Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Additional file 1 of Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders

Autor: Altay, Melek Firat, Liu, Alan King Lun, Holton, Janice L., Parkkinen, Laura, Lashuel, Hilal A.

Additional file 1: Table S1. The primary and secondary antibodies included in this study. AC = autoclave; agg-aSyn = aggregated alpha-synuclein; aSyn = alpha-synuclein; FA = formic acid; GFAP = glial fibrillary acidic protein; Iba1 = ionized calcium

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3448e77291312fd4f79e8b48e01f3b01

Additional file 2 of Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders

Autor: Altay, Melek Firat, Liu, Alan King Lun, Holton, Janice L., Parkkinen, Laura, Lashuel, Hilal A.

Additional file 2: Fig. S1. Specificity validation of the aSyn antibodies LASH-BL 34-45, LASH-BL 80-96 and BD SYN-1 by pre-adsorption followed by IHC on DLB1 cingulate cortex (layers V–VI). aSyn = alpha-synuclein; DLB = dementia with Lewy bodies; I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09529289a5deaa4aa7814b9e5d559d77

Author Correction: Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases.

Autor: Altay MF; Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, EPFL, Lausanne, Switzerland.; Department of Human Genetics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Kumar ST; Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, EPFL, Lausanne, Switzerland., Burtscher J; Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, EPFL, Lausanne, Switzerland., Jagannath S; Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, EPFL, Lausanne, Switzerland., Strand C; Queen Square Brain Bank for Neurological Disorders, University College London Queen Square Institute of Neurology, London, England., Miki Y; Queen Square Brain Bank for Neurological Disorders, University College London Queen Square Institute of Neurology, London, England.; Department of Neuropathology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, 036-8562, Japan., Parkkinen L; Oxford Parkinson's Disease Centre, University of Oxford, Oxford, UK.; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK., Holton JL; Queen Square Brain Bank for Neurological Disorders, University College London Queen Square Institute of Neurology, London, England., Lashuel HA; Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, EPFL, Lausanne, Switzerland. hilal.lashuel@epfl.ch.

Publikováno v: NPJ Parkinson's disease [NPJ Parkinsons Dis] 2024 Jan 11; Vol. 10 (1), pp. 19. Date of Electronic Publication: 2024 Jan 11.